What Nevanac Treats: Main Uses and Benefits

The medication is applied in addressing symptom clusters related to pain and inflammation associated with cataract surgery.

Symptomatic Relief of Acute Post-Surgical Discomfort

The medication is commonly used to help with managing symptoms related to physical discomfort, such as pain, soreness, and aching, that may follow eye surgery. It supports patients during episodes of heightened discomfort and may assist with maintaining functional stability during the recovery phase.

Management of Ocular Swelling and Inflammation

It is applied in addressing symptom clusters related to inflammatory or irritative states, such as swelling (edema) and redness. It is commonly used in situations involving certain distressing symptoms, where it may assist with reducing the risk of conditions characterized by periods of heightened symptoms, such as macular edema, particularly in diabetic patients. This approach contributes to easing the overall symptom load and may assist with maintaining a sense of stability during symptomatic phases.

Briefly, the medication may assist with easing symptoms in conditions involving post-operative ocular pain, localized swelling and redness, and is considered relevant for easing the impact of post-surgical macular edema risk.

---

Quick Fact: Supportive Relief

The medication is commonly used to help manage symptoms that interfere with daily comfort and provides supportive relief when symptoms related to inflammation become more noticeable.

Regulatory References

1. European Medicines Agency (EMA) therapeutic overview

Population Eligibility and Contraindications

Official regulatory documents define specific populations who are permitted, restricted, or prohibited from using Nevanac (nepafenac ophthalmic suspension).

---

Absolute Contraindications

Nevanac is contraindicated in patients with a demonstrated hypersensitivity to the active ingredient, nepafenac, any of its components, or to other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This exclusion includes individuals in whom NSAIDs, such as aspirin, have historically triggered attacks of asthma, urticaria (hives), or acute rhinitis.

---

Restricted and Conditional Use

Eligibility Category	Regulatory Status
Pediatric Patients (Under 10 years)	Safety and effectiveness have not been established.
Late Pregnancy	Use should be avoided due to the known risks of prostaglandin inhibitors on the fetal cardiovascular system.
Comorbidities	Use with caution in patients with pre-existing conditions like diabetes mellitus, rheumatoid arthritis, or known bleeding tendencies.
Corneal Issues	Must be immediately discontinued if evidence of corneal epithelial breakdown occurs.
Contact Lens Wear	The medicine should not be administered while wearing contact lenses.

Nevanac is approved for use in adults and the elderly. For pediatric patients aged 10 years and older, use is established (FDA labeling), although some global regulators recommend against use in those under 18 due to insufficient data. Despite no dedicated studies in patients with renal or hepatic impairment, no dose adjustment is warranted due to the drug's very low systemic absorption. For breastfeeding women, the medicine can be used, as systemic exposure is considered negligible.

Interactions with Other Medicines and Products

This section outlines the officially documented interaction profile for Nevanac (Nepafenac ophthalmic suspension), strictly based on government regulatory information.

---

Pharmacodynamic Interaction Risks

Interacting Product Category	Official Regulatory Classification	Interaction-Related Constraint
Medicines that prolong bleeding time (e.g., blood thinners)	Use with Caution	Concomitant use may increase the risk of hemorrhage due to the potential for NSAIDs to interfere with thrombocyte aggregation.
Topical Corticosteroids (applied to the eye)	Use with Caution	Concomitant use may increase the potential for healing problems as both NSAIDs and corticosteroids can slow or delay healing.
Prostaglandin Analogues (e.g., latanoprost, bimatoprost)	Not Recommended	Concomitant use is not recommended due to very limited data on co-administration.

---

Administration and Clearance Constraints

• Other Topical Ophthalmic Medications: If more than one topical ophthalmic medication is being used (e.g., beta-blockers, carbonic anhydrase inhibitors), the medicines must be administered at least 5 minutes apart. This is a mandatory time-separation rule for co-administration.
• Metabolic Interactions: Drug-drug interactions involving cytochrome P450 (CYP) enzymes are unlikely. In vitro studies demonstrate a very low potential for Nepafenac to inhibit the metabolism of major CYP isozymes, indicating no restriction is required on this basis.
• Contraindicated Class Risk: The medication is contraindicated in patients with a history of hypersensitivity to Nepafenac or to other nonsteroidal anti-inflammatory drugs (NSAIDs), or in whom attacks of asthma or acute rhinitis are precipitated by acetylsalicylic acid (aspirin) or other NSAIDs.

How Nevanac Works: Mechanism of Action

Nevanac (nepafenac) functions as a prodrug, designed for enhanced penetration across the cornea due to its lipophilic nature. Once within the ocular tissues, intraocular hydrolase enzymes catalyze the conversion of nepafenac into its pharmacologically active metabolite, Amfenac.

Amfenac is a non-selective, reversible inhibitor of the Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). By binding to these targets, Amfenac blocks the first committed step in the Arachidonic Acid Cascade, specifically preventing the conversion of arachidonic acid into prostanoids. This inhibition results in the immediate and significant reduction of key lipid mediators, such as PGE2, which modifies the activity of the inflammatory signal transduction cascades within the eye.

The resulting physiological changes include the stabilization of the blood-aqueous barrier activity and a decrease in the sensitization of ocular nerve endings. This mechanism modulates localized vascular responses and affects the transmission of pain signals.

Nevanac is administered exclusively through the topical ocular route as a sterile ophthalmic suspension, applied by instilling one drop into the affected eye. One drop of the 0.1% strength is instilled three times daily (TID). The medication is used in a time-bound course related to cataract surgery.

Treatment must be initiated one day prior to surgery, continued on the day of the procedure, and throughout the postoperative period. An additional single drop must be applied 30 to 120 minutes before the surgery itself, establishing a crucial pre-operative timing requirement. For managing postoperative pain and inflammation, the typical course lasts for the first two weeks (14 days) post-surgery, though this may be extended up to three weeks depending on the region. For reducing the risk of postoperative macular oedema in diabetic patients, the treatment course is specified for up to 60 days following the surgery.

Proper application requires the container to be shaken well immediately prior to each use. If other topical eye drops are prescribed, they must be administered with a minimum separation of five minutes from Nevanac, with any ointments applied last. Dosage adjustments are not generally required for older adults or patients with renal or hepatic impairment due to the medicine’s low systemic absorption. The medicine is not typically recommended for use in children as safety and efficacy data are not fully established in all pediatric age groups. If a dose is missed, a single drop should be administered as soon as feasible, but double doses are prohibited.

Research evidence / Overview of Studies for Nevanac

Evidence for Use in Postoperative Ocular Pain and Inflammation

Research has explored the evaluation of this eye drop in studies conducted following standard cataract removal surgery. The primary research for this indication involved randomized controlled trials (RCTs), where adult participants undergoing routine surgery were assigned to different treatment groups for defined, short-term follow-up durations. These studies focused on measuring objective outcomes related to inflammatory or irritative states, such as the number of inflammatory cells and fluid observed in the eye, and patient-reported outcomes describing perceived discomfort (pain scores).

Research describes how symptoms evolved in the observed populations over time. Findings describe patterns observed in the studies that evaluated changes measured in outcomes related to physical discomfort and inflammation scores over the study period. The trials reported on the percentage of eyes that reached predefined endpoints related to low pain scores and resolution of inflammation scores within the initial recovery timeline, typically in the first few weeks after the procedure. Research provides context but not individual predictions.

---

Evidence for Reducing Risk of Macular Edema in High-Risk Patients

The research focused on evaluating the medication in specific contexts involving patients identified as being at higher risk for certain post-surgical complications, particularly conditions characterized by fluctuating or episodic manifestations like macular edema following cataract surgery in individuals with diabetes. These were intermediate-term RCTs where research examined the incidence of this complication, often tracking changes in the thickness of the macula using specific imaging technology over defined time intervals.

Studies monitored the rate of macular edema occurrence in these high-risk populations. The findings indicate that the research highlights changes measured during the study period, with studies reporting specific rates of macular edema occurrence in the active group compared to the control group over the three-month observation period. Furthermore, the evidence documents that in many of these trials, the eye drop was used in combination with another type of medication (a topical steroid), a factor that is noted in the overall pattern of the findings.

Common questions about Nevanac (FAQ)

---

Q: What is Nevanac (Nepafenac) and how does it work?

Nevanac is an eye drop solution containing the active ingredient nepafenac, belonging to the group of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Official product information indicates that it is a pro-drug that is converted into an active metabolite to help relieve pain and swelling (inflammation) after cataract surgery.

---

Q: What is Nevanac used to treat?

Regulatory documents state that Nevanac is specifically used to prevent and treat pain and inflammation in the eye that occurs following cataract surgery.

This medication is only prescribed for use in adults.

---

Q: Can I use Nevanac if I wear contact lenses?

The official product information advises that you must remove your contact lenses before applying Nevanac eye drops.

Because the eye drops contain the preservative benzalkonium chloride, you should wait at least 15 minutes after using the drops before putting your contact lenses back in.

---

Q: What should I do if I forget a dose of Nevanac?

If a dose is missed, regulatory documents suggest putting the drop in as soon as it's remembered.

However, if it is almost time for the next scheduled dose, the official recommendation is to skip the missed dose and continue with the regular schedule. Never use a double dose to make up for a forgotten one.

---

Q: Can I use Nevanac with other eye medicines?

According to the official product information, if you are using other eye drop medicines, you must space out the application of Nevanac from the other drops.

The regulatory recommendation is to wait at least five minutes between putting in Nevanac and any other eye drop medicine.

---

Q: What are the common side effects of Nevanac?

Common side effects listed in official information include effects such as a feeling of a foreign body in the eye, crusty or sticky eyelids, and eye discomfort.

Less common, but reported, effects include iris inflammation and vision disturbances.

---

Q: How long can I use the bottle of Nevanac after opening it?

Studies and official information indicate that after opening the bottle, Nevanac eye drops must be used within 4 weeks.

Following this period, the official recommendation is that the bottle must be discarded to help ensure the medicine remains safe and effective.

Official Storage and Disposal Requirements

Nevanac (nepafenac ophthalmic suspension) must be stored according to specific regulatory guidelines to maintain its stability.

Storage Requirement	Specification
Temperature	Store between 2 C to 25 C (or not above 30 C).
Prohibited Environment	Keep from freezing (Do not freeze).
Handling	Shake well before use.
Container Rule	Keep the bottle tightly closed when not in use.
Child Safety	Store out of the sight and reach of children.

Stability and Disposal

Once the bottle has been opened, the remainder of the medicine must be discarded after 4 weeks.

Official disposal instructions generally state no special requirements for disposal, but unused medicine should be disposed of in a manner that keeps it out of the reach of children and avoids environmental contamination.